PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma.
Oxford, England, 6th September 2018 PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it acted as exclusive adviser to Vital Food Processors Ltd (“Vital Foods”), an agricultural science company founded in New Zealand, on an asset purchase...
PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.
Oxford, UK, 20 August 2018 PharmaVentures Ltd. (“PharmaVentures”) is pleased to announce that it acted as an independent adviser to SalvaRx Group plc (SALV:LSE) (“SalvaRx”) and Portage Biotech, Inc (“Portage”), on the acquisition of its subsidiary SalvaRx Ltd by...
PharmaVentures Strengthens Its First-Class Strategy Consulting & Dealmaking Capabilities
PharmaVentures strengthens its first class healthcare strategy and dealmaking capabilities with the recruitment of a new Vice President, Ashley Cox. Ashley has built significant industry experience working directly for a number of pharmaceutical companies,...
PharmaVentures Capital Ltd advises Biosceptre International Ltd, a clinical stage oncology company, on its Series A private placement by Tuspark S&T
PharmaVentures Capital Limited is pleased to announce that it acted as adviser to Biosceptre International Limited (“Biosceptre”) for the successful Series A private placement from the Chinese conglomerate Tuspark Science & Technology Service Group (Tuspark)...
PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.
OXFORD, UK, October 28th, 2016 PharmaVentures is pleased to announce that it acted as adviser to IDT Australia Limited for the successful divestment of CMAX, a dedicated clinical trials business, to the Japanese healthcare company I'rom Group Co. Ltd. for a...
PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics
OXFORD, UK, July 27st, 2016PharmaVentures is pleased to announce that it acted as an adviser to the Baylor Scott & White Research Institute in connection with the creation of Denceptor Therapeutics Limited.Denceptor Therapeutics will develop immunotherapeutic...
PharmaVentures expands corporate advisory services through new UK Financial Conduct Authority (FCA) regulated firm
OXFORD, UK, July 21st, 2016 PharmaVentures is pleased to announce that today it has launched a new FCA regulated firm, Pharmaventures Capital Ltd which will carry out all future FCA regulated corporate finance related mandates. The new firm, which is 100% owned by...
PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today
OXFORD, UK, March 22nd, 2016. PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences...
PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility
OXFORD, UK, February 4th, 2016. PharmaVentures is pleased to announce that it acted as an advisor to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc. Transgene...
PharmaVentures advises Stericool on sale to Sweden’s Getinge Group
Oxford, UK, 17th December, 2015. PharmaVentures is pleased to announce that it acted as advisor to Stericool on its sale to Sweden’s Getinge Group, a global leader in infection control and contamination prevention solutions. Stericool specialises in hydrogen...
MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
Oxford, UK, 16th September 2015: PharmaVentures is pleased to announce that it provided transaction support to NovioGendix in its sale to MDxHealth SA (Euronext: MDXH.BR). NovioGendix, a privately-held molecular diagnostics company focused on…
PharmaVentures’ Latest Deal: Douglas Pharmaceuticals acquires Vital Foods’ Phloe product line in New Zealand
OXFORD, UK, September 4th, 2015 PharmaVentures is pleased to announce that it acted as advisor to Douglas Pharmaceuticals, New Zealand's largest pharmaceutical manufacturer, in acquiring from Auckland-based Vital Foods their Phloe® product line in...
PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector
OXFORD, UK, June 30th, 2015 PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT's world leading capabilities in cellular...
Another successful divestment by PharmaVentures
PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection…
PharmaVentures further strengthens its Business Development team
Oxford, UK. March 4th 2015. Following another year of successful deal making, PharmaVentures is pleased to announce the appointment of Graham Combe who has joined its Business Development team. Graham has over 18 years’ experience...
PharmaVentures increases life science presence in the USA
OXFORD, England, February 11th 2015. PharmaVentures is pleased to announce that it is to increase its life science presence in North America by establishing a new base in Boston, MA. Starting this month Dr Adrian Dawkes, VP, will be dividing his time between the USA...
Client News Update: Novartis enters exclusive talks on the potential sale of its UK Horsham site to the University of Brighton
OXFORD, UK, January 27th, 2015. PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015. The University...
PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain
Pharma licensing agreement.
PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.